Back to Journals » Neurobehavioral HIV Medicine » Volume 3

Depression, alcohol abuse, and disclosure of HIV serostatus among rural HIV-positive individuals in western Uganda

Authors Nakimuli-Mpungu E, Munyaneza Godfrey

Published 14 April 2011 Volume 2011:3 Pages 19—25


Review by Single-blind

Peer reviewer comments 2

E Nakimuli-Mpungu1,2, G Munyaneza3,4
1Mental Health Department, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; 2Department of Psychiatry, Makerere College of Health Sciences, School of Medicine, Kampala, Uganda; 3Butabika School of Psychiatric Clinical Officers, Ministry of Education, Kampala, Uganda; 4Rushere Community Hospital, Rushere, Uganda

Introduction: Research into psychological factors associated with disclosure of human immunodeficiency virus (HIV) serostatus in low resource settings is limited. The primary aim of this study was to determine the relationship between depression, alcohol abuse, and disclosure of HIV serostatus to social networks.
Methods: We performed a cross-sectional study in which 244 HIV-positive individuals were examined for disclosure of HIV-positive serostatus and assessed for DSM-IV (Diagnostic Statistical Manual, fourth edition)-defined major depression and alcohol abuse disorder. Multiple regression models were used to determine factors independently associated with major depression, alcohol abuse, and disclosure of HIV serostatus.
Results: Of the 244 study participants, the majority 210 (86%) had disclosed their HIV serostatus. Among those who disclosed their HIV serostatus, 48 (23%) regretted this disclosure. The majority (40%) met DSM-IV criteria for depression, while (7.8%) met DSM-IV criteria for alcohol abuse. Disclosure was protective against alcohol abuse (odds ratio [OR] = 0.21; P = 0.016) but not depression (OR = 0.68; P = 0.38); and was associated with time since HIV diagnosis (OR = 1.39; P = 0.007) and HIV pretest counseling (OR = 3.9; P = 0.045).
Conclusion: Disclosure of HIV serostatus was protective against alcohol abuse but not depression, while regret of disclosure was significantly associated with depression.

Keywords: alcohol abuse, HIVstatus, depression, disclosure

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other articles by this author:

Cross-cultural adaptation and validation of the self-reporting questionnaire among HIV+ individuals in a rural ART program in southern Uganda

Nakimuli-Mpungu E, Mojtabai R, Alexandre PK, Katabira E, Musisi S, Nachega JB, Bass JK

HIV/AIDS - Research and Palliative Care 2012, 4:51-60

Published Date: 12 April 2012

Effect of older age at initiation of antiretroviral therapy on patient retention in an urban ART program in Uganda

Etheldreda Nakimuli-Mpungu, Noeline Nakasujja, Howard Dickens Akena, et al

Neurobehavioral HIV Medicine 2011, 3:1-8

Published Date: 16 December 2010

Effect of HIV infection on time to recovery from an acute manic episode

E Nakimuli-Mpungu, B Mutamba, S Nshemerirwe, et al

HIV/AIDS - Research and Palliative Care 2010, 2:185-189

Published Date: 29 September 2010

Readers of this article also read:

Perioperative management of hemophilia patients receiving total hip and knee arthroplasty: a complication report of two cases

Tateiwa T, Takahashi Y, Ishida T, Kubo K, Masaoka T, Shishido T, Sano K, Yamamoto K

Therapeutics and Clinical Risk Management 2015, 11:1383-1389

Published Date: 15 September 2015

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

Profile of efraloctocog alfa and its potential in the treatment of hemophilia A

George LA, Camire RM

Journal of Blood Medicine 2015, 6:131-141

Published Date: 24 April 2015

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Neuropsychiatric Disease and Treatment 2014, 10:865-867

Published Date: 16 May 2014

Managing hemophilia: the role of mobile technology

Khair K, Holland M

Smart Homecare Technology and TeleHealth 2014, 2:39-44

Published Date: 6 May 2014

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

International Journal of Nanomedicine 2010, 5:581-591

Published Date: 6 August 2010